Celofos 2000 is a combination chemotherapy treatment that includes ifosfamide, an alkylating agent used to kill cancer cells, and mesna, a protective agent that helps reduce the risk of harmful effects on the bladder caused by ifosfamide. This combination is typically administered intravenously under the supervision of experienced healthcare professionals in a hospital or oncology setting. Celofos is an important option in the treatment of certain aggressive or advanced-stage cancers.

Mechanism of Action

• Ifosfamide works by interfering with the DNA of rapidly dividing cancer cells. It introduces chemical bonds in the DNA strands, preventing them from copying properly. This halts cell replication and leads to cell death, particularly in fast-growing cancer cells.

• Mesna (mercaptoethane sulfonate sodium) does not treat cancer itself but plays a crucial role in protecting the bladder lining. It binds with toxic byproducts of ifosfamide in the urine and neutralises them, thereby reducing the risk of hemorrhagic cystitis, a serious bladder-related side effect.

  Uses

  Celofos 2000 is used in the treatment of various cancers, including:

  • Testicular cancer, particularly when other treatments have not worked

  • Lymphomas such as non-Hodgkin and Hodgkin lymphoma

  • Sarcomas including soft tissue and bone sarcomas

  • Lung cancer

  • Cervical and ovarian cancer in selected cases

    Adverse Effects

    Common Side Effects

    • Nausea and vomiting

    • Fatigue and weakness

    • Hair loss

    • Low blood cell counts, increasing the risk of infections, anemia, or bleeding

    • Loss of appetite